AstraZeneca therapy works against Omicron; results mixed for Regeneron



* Evusheld retains neutralising activity against Omicron

* REGEN-COV showed diminished potency; active against Delta

* More data on AstraZeneca's Evusheld expected 'very soon' (Writes through with details on AstraZeneca's drug, background)

By Mrinalika Roy and Pushkala Aripaka

Dec 16 (Reuters) - AstraZeneca AZN.L and Regeneron REGN.O on Thursday reported contrasting data on the effectiveness of their COVID-19 antibody therapies against the Omicron variant of the coronavirus, underscoring the major challenges ahead for drugmakers.

U.S.-based Regeneron said its REGEN-COV therapy, also called Ronapreve, is less effective against Omicron, though it is still active against the Delta variant, confirming indications from lab tests and computer modelling late last month.

Anglo-Swedish rival AstraZeneca, however, said a lab study found that its antibody cocktail Evusheld retained neutralising activity against Omicron, the first such data for the treatment.

The new variant has been detected in 77 countries since it was first identified three weeks ago, fuelling concerns that its large number of mutations will help it spread faster and evade protection provided by COVID-19 vaccines and therapeutics.

Earlier this week, German researchers found that COVID-19 therapies developed by Eli Lilly LLY.N and Regeneron lose most of their effectiveness when exposed in laboratory tests to Omicron.

But lab studies this week showed GSK-Vir's GSK.L VIR.O antibody treatment retains neutralizing activity against all tested coronavirus variants, including Omicron.

The study on Evusheld was done by independent investigators of the U.S. Food and Drug Administration using so-called pseudoviruses that feature major coronavirus mutations across suspicious variants that have emerged so far.

ROAD AHEAD

The researchers found the potency of Evusheld was within the ranges seen in those previously infected with COVID-19, showing promise for wide use of the therapy, which is the first preventative shot other than vaccines against the coronavirus.

AstraZeneca said more analyses of Evusheld against Omicron are being conducted by the company and third parties, with data expected "very soon."

Regeneron said REGEN-COV is still active against Delta, which currently is the most prevalent variant in the United States.

The European Union's public health body, however, warned on Wednesday that there was a "very high" risk Omicron would become dominant in Europe by early next year.

REGEN-COV is currently authorized for use in the United States to treat people with mild-to-moderate COVID-19 and for prevention of infection in those exposed to infected individuals, and others at high risk of exposure.

Evusheld has been granted authorisation to prevent COVID-19 infections in individuals with weak immune systems or a history of severe side-effects from coronavirus vaccines.

Both treatments belong to a class of medicines called monoclonal antibodies which mimic natural antibodies in fighting off infections.

Unlike vaccines, they do not rely on the body to create an immune response, and can therefore help individuals with weak or compromised immune systems.
Reporting by Mrinalika Roy and Pushkala Aripaka in Bengaluru; Editing by Shailesh Kuber and Paul Simao

免責聲明: XM Group提供線上交易平台的登入和執行服務,允許個人查看和/或使用網站所提供的內容,但不進行任何更改或擴展其服務和訪問權限,並受以下條款與條例約束:(i)條款與條例;(ii)風險提示;(iii)完全免責聲明。網站內部所提供的所有資訊,僅限於一般資訊用途。請注意,我們所有的線上交易平台內容並不構成,也不被視為進入金融市場交易的邀約或邀請 。金融市場交易會對您的投資帶來重大風險。

所有缐上交易平台所發佈的資料,僅適用於教育/資訊類用途,不包含也不應被視爲適用於金融、投資稅或交易相關諮詢和建議,或是交易價格紀錄,或是任何金融商品或非應邀途徑的金融相關優惠的交易邀約或邀請。

本網站的所有XM和第三方所提供的内容,包括意見、新聞、研究、分析、價格其他資訊和第三方網站鏈接,皆爲‘按原狀’,並作爲一般市場評論所提供,而非投資建議。請理解和接受,所有被歸類為投資研究範圍的相關内容,並非爲了促進投資研究獨立性,而根據法律要求所編寫,而是被視爲符合營銷傳播相關法律與法規所編寫的内容。請確保您已詳讀並完全理解我們的非獨立投資研究提示和風險提示資訊,相關詳情請點擊 這裡查看。

我們運用 cookies 提供您最佳之網頁使用經驗。更改您的cookie 設定跟詳情。

風險提示:您的資金存在風險。槓桿商品並不適合所有客戶。請詳細閱讀我們的風險聲明